Dirk Sibbing on OCEANIC-STROKE Demonstrationg Superiority of Asundexian vs. Placebo
Dirk Sibbing, Professor, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, shared on LinkedIn:
”Positive late-breaking news on a new pathway – Factor XIa inhibition – for antithrombotic treatment for stroke risk reduction
Secondary prevention trial in patients (>12,000 pts) after non-cardioembolic ischemic stroke or high-risk TIA
OCEANIC-STROKE demonstrates superiority of asundexian vs. Placebo (in both study arms in combo with antiplatelet therapy), showing significant reduction in ischemic stroke risk, without increasing bleeding risk
OCEANIC-STROKE is the first successfully completed Phase III study of a Factor XIa inhibitor (50 mg p.o. once daily)
Adding an antithrombotic agent (here: asundexian) to best medical treatment (here: antiplatelet treatment) with significant reduction in ischemic risk and – at the same time – without (!) increasing overall bleeding risk is highly remarkable!
Uncoupling thrombosis- and haemostasis risk”
Read the full article here.
Stay updated with Hemostasis Today.
-
May 24, 2026, 12:04Kalpana Gupta Shekhawat: Ferritin Is More Than an Iron Marker
-
May 24, 2026, 11:50Peter Zdziarski: Making Rare Disease Research More Human
-
May 24, 2026, 11:39Bram Berkelmans: Donating with a View
-
May 24, 2026, 11:28Ratiporn Chinthammit: A Meaningful Exchange in aHUS and PNH Education
-
May 24, 2026, 11:17Mary Ann Sromoski: Transfusion Medicine and Patient Blood Management in Practice
-
May 24, 2026, 07:45Thierry Burnouf: Advances in Platelet Membrane-Coated Nanoparticles for Targeted Therapeutics and Regenerative Medicine
-
May 24, 2026, 07:39Shamala Thilarajah: Our Team Receives the NMRC Transition Award for NEUROACT-Stroke
-
May 24, 2026, 05:48Yazan Abou-Ismail: Contributing to the Future of von Willebrand Disease Management
-
May 24, 2026, 05:47Ali AlBahar: The Immunologic Complexity Behind ABO Blood Grouping